The effects of metformin on vascular function and adipocyte AMP-activated protein kinase (AMPK) activation in type 2 diabetes

The effects of metformin on vascular function and adipocyte AMP-activated protein kinase (AMPK) activation in type 2 diabetes: a randomised, double blind, glycaemia-controlled crossover trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51336867

Enrollment

Registered

2010-06-29

Start date

2004-03-09

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Interventions

The study was single-centre and had a randomised, double blind, glycaemia-controlled crossover design. After full explanation of experimental procedures aided by a subject information sheet, written i

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Body mass index (BMI) range 27 - 40 kg/m2 2. HbA1c greater than 7% but less than 11% (Diabetes Control and Complications Trial [DCCT]) at screening 3. Previously treated with diet alone or oral monotherapy (i.e., metformin or sulphonylurea). Subjects on monotherapy had discontinued medication during the six-week run-in period. 4. Males, aged between 50 - 70 years

Exclusion criteria

Exclusion criteria: 1. Subjects on warfarin treatment 2. Subjects treated with insulin currently or in the previous 12 months 3. Previous intolerance of metformin or sulphonylurea 4. Presence of contra-indication to metformin therapy for example renal disease or congestive cardiac failure 5. Cardiovascular event (i.e., electrocardiogram (ECG)/troponin proven myocardial infarction [MI] or cerebrovascular accident [CVA]) in previous 6 months

Design outcomes

Primary

Measure	Time frame
Measured at the end of each 10-week study phase: 1. Body mass index 2. Blood pressure 3. Analysis of routine blood samples (fasting venous blood samples for urea, creatinine, electrolytes, total cholesterol, triglycerides, high density lipoprotein [HDL]-cholesterol, loew density lipoprotein [LDL]-cholesterol, glucose, liver function tests and HbA1C) 4. Analysis of non-routine blood samples (total adiponectin, tumour necrotising factor-alpha [TNF-a], interleukin-6 [IL-6] and asymmetric dimethyl-arginine [ADMA]) 5. Pulse wave velocity (PWV) 6. Wire myography 7. Adipose AMPK activity assays	—

Measure

Time frame

Measured at the end of each 10-week study phase: 1. Body mass index 2. Blood pressure 3. Analysis of routine blood samples (fasting venous blood samples for urea, creatinine, electrolytes, total cholesterol, triglycerides, high density lipoprotein [HDL]-cholesterol, loew density lipoprotein [LDL]-cholesterol, glucose, liver function tests and HbA1C) 4. Analysis of non-routine blood samples (total adiponectin, tumour necrotising factor-alpha [TNF-a], interleukin-6 [IL-6] and asymmetric dimethyl-arginine [ADMA]) 5. Pulse wave velocity (PWV) 6. Wire myography 7. Adipose AMPK activity assays

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 29, 2026